Bonothyrk (20mg)

What is Bonothyrk?

A short-peptide bioregulator from the Khavinson series, sourced and studied for parathyroid-tissue-specific gene-expression modulation in calcium-homeostasis research.

Listed vial contents: 20mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

What mechanisms are being studied?

Bonothyrk is a short-peptide bioregulator from the Khavinson series, developed at the St. Petersburg Institute of Bioregulation and Gerontology. Like other bioregulators in this class, it is hypothesized to bind specific DNA promoter sequences in parathyroid tissue, modulating expression of genes involved in parathyroid hormone (PTH) synthesis and calcium-homeostasis signaling. Khavinson-class peptides are characterized by very short sequences (2–4 amino acids), tissue-specific activity, and low effective doses.

What are the research questions?

• Calcium-homeostasis research: Used in animal models of age-related parathyroid dysfunction to study PTH secretion and serum calcium regulation.
• Bone-metabolism research: Investigated as part of bone-health bioregulator stacks alongside cartilage-targeted (Cartalax) and bone-targeted (Sigumir) peptides.
• Bioregulator-pathway research: Provides a parathyroid-specific tool in studies comparing tissue-selective gene-expression modulation across the Khavinson series.
• Geriatric-endocrinology models: Used in preclinical models examining age-related decline in parathyroid responsiveness.

What does the published work describe?

Khavinson VKh et al. (Bull Exp Biol Med, various 2003–2018) — series of publications documenting tissue-specific gene-expression and functional effects of Khavinson short-peptide bioregulators in animal models. Published data on Bonothyrk specifically is limited and primarily Russian-language; mechanism is inferred from the broader bioregulator literature.

What are the limits of this evidence?

The research described concerns the cited experimental materials and models, not proof that this supplied vial is a treatment. Cell or animal findings do not establish human benefits. Clinical findings, where cited, apply to the tested formulation and population; they do not validate this research product for human use.

Study references

1. Khavinson VKh. Bull Exp Biol Med 2003 — peptide bioregulators
2. Khavinson VKh, Malinin VV. Gerontological Aspects of Genome Peptide Regulation, 2005
3. Anisimov VN, Khavinson VKh. Biogerontology 2010

These are the catalog's existing bibliographic references. No new source verification is implied by this presentation.

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. Generated sample reports illustrate the reporting flow and are not evidence of testing, purity or accreditation.